DOCSLIB.ORG

GRAS Notifications to FDA – a Review of Ingredients with Intended Use In

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
GRAS Notifications to FDA – a Review of Ingredients with Intended Use In GRAS Ingredients for Use in Medical Foods GRAS Ingredients for Use in Medical Foods: An Overview of FDA Regulation Ginny Bank, Cheryl Dicks, MS, RAC 1 © GRAS Associates 2016 www.gras-associates.com GRAS Ingredients for Use in Medical Foods Contents Introduction ..................................................................................................... 3 FDA Medical Food Regulation Overview ........................................................ 4 GRAS Notifications to FDA – A Review of Ingredients with Intended Use in Medical Foods ................................................................................................. 6 Ready to seek GRAS status for your medical food ingredient? ................. 11 Regulatory Services Include: ..................................................................... 11 Uncover greater market opportunities for your ingredient ......................... 12 Contact GRAS Associates today ............................................................... 12 Appendix A – Summary of GRAS Notifications Submitted to FDA for Ingredients Intended for Use in Medical Foods .......................................... 13 2 © GRAS Associates 2016 www.gras-associates.com GRAS Ingredients for Use in Medical Foods Introduction The medical food arena is a growing specialty product category that presents food and dietary supplement manufactures with interesting business opportunities for market expansion of an ingredient or final product. The Business Insights: The Emerging Market for Medical Foods Nutraceuticals World report states that the U.S. has seen over 100 new medical foods enter the marketplace since 2009. Medical foods marketing does, however, present regulatory challenges within the “gray zone” of regulation and guidance for medical foods as overseen by the Food and Drug Administration (FDA). In this article, you will learn: What products/ingredients are classified as medical foods How medical foods differ from conventional foods, dietary supplements and specialty foods Specific regulatory requirements for medical foods as overseen by the FDA What you need to do to ensure your medical food complies with the regulations The benefits of Generally Recognized as Safe (GRAS) regulatory filings for medical food ingredients Which ingredients have already achieved GRAS status in marketplace Common reasons for FDA warning letters for medical foods How to avoid getting an FDA warning letter 3 © GRAS Associates 2016 www.gras-associates.com GRAS Ingredients for Use in Medical Foods FDA Medical Food Regulation Overview A medical food, is defined in section 5(b)(3) of the 1988 Orphan Drug Act (ODA) (21 U.S.C. 360ee(b)(3)). This category is defined as “a food which is formulated to be consumed or administered enterally under the supervision of a physician and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation.” The Agency, in 1996, published solicited comments on their advance notice of proposed rulemaking (ANPRM) for this broad category of “foods.” The ANPRM was removed in 2004 and revised as a question and answer guidance document in 2007. In 2013, FDA published a revised version of its 2007 draft guidance for medical foods, Draft Guidance for Industry: Frequently Asked Questions About Medical Foods; Second Edition. This was recently followed up with the Final Guidance on Frequently Asked Questions About Medical Foods. This revised guidance reflects FDA’s viewpoint that the statutory definition of medical foods is to be narrowly constrained to the types of products that fit within this category of food and to distinguish them from “specialty foods,” outlining the criteria. According to the final guidance, a medical food: Provides distinctive nutritional requirements, not met by alteration to normal diet; Can be foods intended for persons not able to ingest foods in certain physical forms; i.e., partial or exclusive oral intake or enteral tube feeding; Is an integral part of the patent's clinical management under medical supervision; Is intended for the "specific dietary management" of a disease or condition; 4 © GRAS Associates 2016 www.gras-associates.com GRAS Ingredients for Use in Medical Foods Is a food that is processed or specially formulated and not in its “natural” state. Furthermore, according to the FDA’s Compliance Program for Medical Foods, medical foods are classified into the following categories: a) Nutritionally complete formulas; b) Nutritionally incomplete formulas, including individual "modular" type products that may be mixed with other products before use (e.g., protein, carbohydrate, or fat modulars); c) Formulas for metabolic (genetic) disorders in patients over 12 months of age; or d) Oral rehydration products. There is much confusion around what type of food or dietary ingredient qualifies as a medical food. It is important note that medical food are NOT foods used in their “natural state” or dietary supplements simply recommended by a physician as part of an overall diet to manage the symptoms or reduce the risk of a disease or condition, and all foods fed to sick patients are not medical foods. Medical foods are foods that are specially formulated and processed for a patient who is seriously ill or who requires use of the product as a major component of a disease or condition’s specific dietary management and cannot be achieved by changes to a normal diet. In addition, medical foods must also comply with all applicable requirements for the manufacture of foods. Ingredients used in medical foods must be approved food additives or a food additive that is the subject of an exemption for investigational use (21 U.S.C. 321 and 348), if the ingredients are not Generally Recognized as Safe (GRAS). 5 © GRAS Associates 2016 www.gras-associates.com GRAS Ingredients for Use in Medical Foods GRAS Notifications to FDA – A Review of Ingredients with Intended Use in Medical Foods In an attempt to gain insight on defining the “gray zone” of medical food regulation as well as a better understanding of FDA’s viewpoint in the regulation of this category of foods which allows for permissible health and disease claims, a review of GRAS notifications to FDA, identifying medical foods as one of the food uses, is warranted. The review investigated whether the GRAS notification treated the intended use of the ingredient in medical foods differently than its use in conventional foods. A number of companies have notified FDA of GRAS determinations for ingredients with an intended use in medical foods (A summary of these ingredients is supplied in Appendix A). The majority of the ingredients were found to be sources of specific nutrients such as dietary sources of carotenoids, making up the largest number of medical food use determinations (GRN 110 and 140), minerals, fatty acids and fiber. Two submissions were for ingredients with a functional effect in the final product (e.g., sugar substitutes) and two fit neither category. Some GRAS notifications to the FDA were amended after receiving a GRN number to include medical foods as observed with the notification of tomato extract (GRN 156) and tomato pulp powder (GRN 163); specifically determining the use of these ingredients in medical foods to be GRAS. In these amendments, the notifier states that “because there is no specific deficiency, disease, syndrome or symptom arising from an absence of lycopene, the addition of lycopene, in and by itself, cannot render a food a ‘medical food’ simply as the result of its addition to the food. In this GRAS notification, tomato extract of lycopene is to be added to foods already determined to be medical foods.” The amendments also include a very detailed definition of a medical food and a detailed evaluation of the dietary 6 © GRAS Associates 2016 www.gras-associates.com GRAS Ingredients for Use in Medical Foods exposure for patients who will consume lycopene from a medical food in addition to conventional foods and dietary supplements containing lycopene. In addition, the amendments state that since medical foods are administered under supervision of a physician, it is therefore unlikely that there would be an overconsumption of lycopene. Both of the amendments received “No Questions” responses from FDA. The use of palm oil-derivedcarotenoids (GRN 320) included medical foods in the intended uses noting a specific medical food use is for the treatment of erythropoietic protoporphyria. FDA responded with a “No Questions” letter. The medical food use of selenium (GRN 260) received a “No Questions” response from FDA, for use to “facilitate avoidance of selenium deficiency to this essential micronutrient.” The notification assumes that the medical foods uses would replace 20 servings per day of traditional foods and further noted that the medical food use is to be under the supervision of a physician, intake of the ingredient would be monitored to ensure safe use. GRN 260 received a “No Questions” response from FDA. A second notification for selenium (GRN 353) also considers the use of medical foods as a supplement to the typical diet (when the medical food is not the sole source of the diet), but notes that since medical foods are administered under supervision of a physician, it is “likely that the physician is cognizant of the need for adequate amounts of selenium and the possible overdosing of selenium and therefore, will advise the patient
Load more

Recommended publications
  • Determining the Effect of Small Doses of Fructose and Its Epimers on Glycemic Control
    Determining the Effect of Small Doses of Fructose and its Epimers on Glycemic Control by Jarvis Clyde Noronha A thesis submitted in conformity with the requirements for the degree of Master of Science Department of Nutritional Sciences University of Toronto © Copyright by Jarvis Clyde Noronha 2017 ii Determining the Effect of Small Doses of Fructose and its Epimers on Glycemic Control Jarvis Clyde Noronha Master of Science Department of Nutritional Sciences University of Toronto 2017 Abstract Given that sugars have emerged as the dominant nutrient of concern in diabetes, there is a need for the development of alternative sweeteners. To assess the role of small doses (5g, 10g) of fructose and allulose on postprandial glucose metabolism, we conducted an acute randomized controlled trial in individuals with type 2 diabetes. We found that small doses of allulose, but not fructose, modestly reduced the postprandial glycemic response to a 75g oral glucose load. To assess whether low-dose (< 50-g/day) fructose and all its epimers (allulose, tagatose and sorbose) lead to sustainable improvements in long-term glycemic control, we conducted a systematic review and meta-analysis of controlled feeding trials. The available evidence suggested that fructose and tagatose led to significant reductions in HbA1c and fasting glucose. Our findings highlight the need for long-term randomized controlled trials to confirm the viability of fructose and its epimers as alternative sweeteners. iii Table of Contents Contents Abstract ...........................................................................................................................
    [Show full text]
  • FDA Finalizes Allulose Guidance and Requests Information on Other Sugars Metabolized Differently Than Traditional Sugars
    FDA Finalizes Allulose Guidance and Requests Information on Other Sugars Metabolized Differently Than Traditional Sugars October 19, 2020 Food, Drug, and Device FDA has taken two notable actions regarding the sugars declaration in the Nutrition Facts Label (NFL) and Supplement Facts Label (SFL). On Friday, the agency released a final guidance regarding the declaration of allulose, confirming that this monosaccharide need not be included in the declaration of “Total Sugars” or “Added Sugars,” though it must be included in the “Total Carbohydrates” declaration in the NFL. Today, FDA published a Federal Register notice requesting information about and comments on the nutrition labeling of other sugars that are metabolized differently than traditional sugars. We briefly summarize both documents below to help inform stakeholder comments on the notice, which are due to FDA by December 18, 2020. Allulose Final Guidance Allulose, or D-psicose, is a monosaccharide that can be used as a substitute for traditional sugar in food and beverage products. For purposes of nutrition labeling, FDA has generally 1 defined nutrients based on their chemical structure.0F Accordingly, when FDA updated its NFL and SFL regulations in 2016, the agency reiterated the definition of “Total Sugars” as the sum of 2 all free monosaccharides and disaccharides (e.g. glucose, fructose, and sucrose).1F FDA also added to these regulations a definition of “Added Sugars” – sugars added during the processing 3 of food, or packaged as such – and required their declaration in the NFL and SFL.2F Although the agency recognized that there are sugars that are metabolized differently than traditional sugars, FDA did not make a determination at that time as to whether allulose should be excluded from “Total Carbohydrate,” “Total Sugars,” or “Added Sugars” Declarations.
    [Show full text]
  • Effects of D-Allulose on Glucose Tolerance and Insulin Response to A
    Clinical care/Education/Nutrition Open access Original research BMJ Open Diab Res Care: first published as 10.1136/bmjdrc-2020-001939 on 26 February 2021. Downloaded from Effects of D- allulose on glucose tolerance and insulin response to a standard oral sucrose load: results of a prospective, randomized, crossover study Francesco Franchi ,1 Dmitry M Yaranov,1 Fabiana Rollini,1 Andrea Rivas,1 Jose Rivas Rios,1 Latonya Been,1 Yuma Tani,2 Masaaki Tokuda,3 Tetsuo Iida,2 Noriko Hayashi,2 Dominick J Angiolillo,1 Arshag D Mooradian1 To cite: Franchi F, Yaranov DM, ABSTRACT Rollini F, et al. Effects of D- Introduction Current dietary guidelines recommend Significance of this study allulose on glucose tolerance limiting sugar intake for the prevention of diabetes and insulin response to a mellitus (DM). Reduction in sugar intake may require sugar What is already known about this subject? standard oral sucrose load: substitutes. Among these, D- allulose is a non- calorie rare ► D- allulose is defined one of the rare sugars, results of a prospective, which has been shown in animal and clinical randomized, crossover study. monosaccharide with 70% sweetness of sucrose, which has shown anti- DM effects in Asian populations. However, studies, conducted mostly in Asian populations, BMJ Open Diab Res Care to have postprandial plasma glucose suppres- 2021;9:e001939. doi:10.1136/ there is limited data on the effects of D- allulose in other sive effects with antiobesity and antidiabetic bmjdrc-2020-001939 populations, including Westerners. Research design and methods This was a prospective, effects. copyright. randomized, double- blind, placebo- controlled, crossover What are the new findings? ► Supplemental material is study conducted in 30 subjects without DM.
    [Show full text]
  • Natural Alternative Sweeteners and Diabetes Management
    Current Diabetes Reports (2019) 19:142 https://doi.org/10.1007/s11892-019-1273-8 LIFESTYLE MANAGEMENT TO REDUCE DIABETES/CARDIOVASCULAR RISK (B CONWAY AND H KEENAN, SECTION EDITORS) Natural Alternative Sweeteners and Diabetes Management Emily Mejia1 & Michelle Pearlman2 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of Review The goal of this review is to discuss the data on natural alternative sweeteners and their effects on glucose homeostasis and other metabolic parameters within the past five years. We sought to answer whether common natural alternative sweeteners have a positive or negative effect on glucose control in both human and animal models, and whether the data supports their widespread use as a tool to help reduce the prevalence of diabetes and associated comorbid conditions. Recent Findings Recent studies suggest that natural alternative sweeteners may reduce hyperglycemia, improve lipid metabo- lism, and have antioxidant effects particularly in those that have baseline diabetes. Summary Diabetes and metabolic syndrome have become a global healthcare crisis and the sugar overconsumption plays a major role. The use of artificial sweeteners has become more prevalent to improve insulin resistance in those with diabetes, obesity, and metabolic syndrome, although the evidence does not support this result. There are however some promising data to suggest that natural alternative sweeteners may be a better alternative to sugar and artificial sweeteners. Keywords Natural alternative sweeteners . Diabetes . Stevia . Sugar alcohols . Rare sugars Introduction retinopathy, nephropathy, cerebrovascular disease, peripheral vascular disease, and cardiovascular disease [2–4]. Type 2 Diabetes mellitus (DM) is a metabolic disorder that results DM (T2DM) often coexists with other metabolic disorders from glucose dysregulation.
    [Show full text]
  • Calorie Restriction Mimetics: Upstream-Type Compounds for Modulating Glucose Metabolism
    nutrients Review Calorie Restriction Mimetics: Upstream-Type Compounds for Modulating Glucose Metabolism Hideya Shintani 1 , Tomoya Shintani 2,* , Hisashi Ashida 3 and Masashi Sato 4 1 Department of Internal Medicine, Saiseikai Izuo Hospital, Osaka 551-0032, Japan; [email protected] 2 United Graduate School of Agricultural Science, Ehime University, Matsuyama 790-8577, Japan 3 Faculty of Biology-Oriented Science and Technology, Kindai University, Wakayama 649-6493, Japan; [email protected] 4 Faculty of Agriculture, Kagawa University, Kagawa 761-0701, Japan; [email protected] * Correspondence: [email protected]; Tel.: +81-6-6621-5122 Received: 6 November 2018; Accepted: 18 November 2018; Published: 22 November 2018 Abstract: Calorie restriction (CR) can prolong the human lifespan, but enforcing long-term CR is difficult. Therefore, a compound that reproduces the effect of CR without CR is needed. In this review, we summarize the current knowledge on compounds with CR mimetic (CRM) effects. More than 10 compounds have been listed as CRMs, some of which are conventionally categorized as upstream-type CRMs showing glycolytic inhibition, while the others are categorized as downstream-type CRMs that regulate or genetically modulate intracellular signaling proteins. Among these, we focus on upstream-type CRMs and propose their classification as compounds with energy metabolism inhibition effects, particularly glucose metabolism modulation effects. The upstream-type CRMs reviewed include chitosan, acarbose, sodium-glucose cotransporter 2 inhibitors, and hexose analogs such as 2-deoxy-D-glucose, D-glucosamine, and D-allulose, which show antiaging and longevity effects. Finally, we discuss the molecular definition of upstream-type CRMs.
    [Show full text]
  • D-Allulose Is a Substrate of Glucose Transporter Type 5 (GLUT5) in the Small Intestine
    Food Chemistry 277 (2019) 604–608 Contents lists available at ScienceDirect Food Chemistry journal homepage: www.elsevier.com/locate/foodchem D-Allulose is a substrate of glucose transporter type 5 (GLUT5) in the small intestine T ⁎ Kunihiro Kishidaa, , Gustavo Martinezb, Tetsuo Iidac, Takako Yamadac, Ronaldo P. Ferrarisb,1, Yukiyasu Toyodad,1 a Department of Science and Technology on Food Safety, Kindai University, 930 Nishimitani, Kinokawa, Wakayama 649-6493, Japan b Department of Pharmacology, Physiology, and Neurosciences, New Jersey Medical School, Rutgers University, 185 S. Orange Avenue, Newark, NJ 07101-1749, USA c Research and Development, Matsutani Chemical Industry Company, Limited, 5-3 Kita-Itami, Itami, Hyogo 664-8508, Japan d Department of Pathobiochemistry, Faculty of Pharmacy, Meijo University, 150 Yagotoyama, Tempaku-ku, Nagoya, Aichi 468-8503, Japan ARTICLE INFO ABSTRACT Keywords: D-Allulose has been reported to have beneficial health effects. However, the transport system(s) mediating in- D-Allulose testinal D-allulose transport has not yet been clearly identified. The aim of this study was to investigate whether Intestinal absorption intestinal D-allulose transport is mediated by glucose transporter type 5 (GLUT5). When D-allulose alone was GLUT5 gavaged, plasma D-allulose levels were dramatically higher in rats previously fed fructose. This suggests en- hanced intestinal D-allulose absorption paralleled increases in GLUT5 expression observed only in fructose-fed rats. When D-allulose was gavaged with D-fructose, previously observed increases in plasma D-allulose levels were dampened and delayed, indicating D-fructose inhibited transepithelial D-allulose transport into plasma. Tracer D- 14 [ C]-fructose uptake rate was reduced to 54.8% in 50 mM D-allulose and to 16.4% in 50 mM D-fructose, sug- 14 gesting D-allulose competed with D-[ C]-fructose and the affinity of D-allulose for GLUT5 was lower than that of D-fructose.
    [Show full text]
  • D-Psicose Nutrasource, Inc.Inc
    ORIGINAL SUBMISSION 000001 GRAS exemption claim for D-psicose NutraSource, Inc.Inc. August 18,18, 20112011 Dr. Susan CarlsonCarlson Division ofof BiotechnologyBiotechnology andand GRASGRAS NoticeNotice ReviewReview Office of Food AdditiveAdditive Safety-CFSANSafety-CFSAN U.S. Food andand DrugDrug AdministrationAdministration 5100 Paint Branch ParkwayParkway (HFS-255)(HFS-255) College Park, MDMD 20740-383520740-3835 DiVisionDivision of BiotechnologyBiotechnology and GRAS Notice ReviewReview Re: GRAS exemption claimclaim forfor D-psicoseD-psicose asas anan ingredientingredient inin foodsfoods Dear Dr. Carlson,Carlson, This is to notify you that CJCJ CheiljedangCheiljedang (based(based inin S.S. Korea)Korea) claimsclaims thatthat thethe useuse ofof thethe substance described below (D-psicose) is exempt fromfrom the the premarketpremarket approvalapproval requirementsrequirements ofof the Federal Food, Drug, and CosmeticCosmetic ActAct becausebecause CJCJ AmericaAmerica hashas determineddetermined suchsuch useuse toto bebe Generally Recognized AsAs SafeSafe (GRAS).(GRAS). On behalf ofCJof CJ Cheiljedang, NutraSource (an independent consultingconsulting firm)firm) assembledassembled aa panel of experts highly qualified byby scientificscientific trainingtraining andand experienceexperience toto evaluateevaluate thethe safetysafety ofof the intended uses ofofD-psicose. D-psicose. The panel includedincluded Dr.Dr. SusanSusan ChoCho atat NutraSourceNutraSource (Clarksville,(Clarksville, MD), Dr. Joanne Slavin (The University ofof Minnesota,Minnesota,
    [Show full text]
  • Potent Inhibitory Effects of D-Tagatose on the Acid Production and Water-Insoluble Glucan Synthesis of Streptococcus Mutans GS5 in the Presence of Sucrose
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Okayama University Scientific Achievement Repository Acta Med. Okayama, 2015 Vol. 69, No. 2, pp. 105ﾝ111 CopyrightⒸ 2015 by Okayama University Medical School. Original Article http ://escholarship.lib.okayama-u.ac.jp/amo/ Potent Inhibitory Effects of D-tagatose on the Acid Production and Water-insoluble Glucan Synthesis of Streptococcus mutans GS5 in the Presence of Sucrose Daijo Sawadaa,b＊, Takaaki Ogawaa, Minoru Miyakea, Yoshinori Hasuib, Fuminori Yamaguchic, Ken Izumorid, and Masaaki Tokudac,d Departments of aOral and Maxillofacial Surgery and cCell Physiology, Faculty of Medicine, Kagawa University, Miki, Kagawa 761-0793, Japan, bHasui Dental Family Clinic, Kagawa 761-0704, Japan, dRare Sugar Research Center, Miki, Kagawa 761-0793, Japan We examined and compared the inhibitory effects of D-tagatose on the growth, acid production, and water-insoluble glucan synthesis of GS5, a bacterial strain of Streptococcus mutans, with those of xylitol, D-psicose, L-psicose and L-tagatose. GS5 was cultured for 12h in a medium containing 10ｵ (w/v) of xylitol, D-psicose, L-psicose, D-tagatose or L-tagatose, and the inhibitory effect of GS5 growth was assessed. Each sugar showed different inhibitory effects on GS5. Both D-tagatose and xylitol significantly inhibited the acid production and water-insoluble glucan synthesis of GS5 in the presence of 1ｵ (w/v) sucrose. However, the inhibitory effect of acid production by D-tagatose was significantly stronger than that of xylitol in presence of sucrose. Key words: Streptococcus mutans, D-tagatose, xylitol, acid production, water-insoluble glucan he definition of ʻrare sugarsʼ is monosaccha- the most extensively examined rare sugar, including T raides and their derivatives that are not com- anti-diabetes and anti-obesity effects [4-7].
    [Show full text]
  • GRAS Notice 828, D-Psicose
    GRAS Notice (GRN) No. 828 https://www.fda.gov/food/generally-recognized-safe-gras/gras-notice-inventory NutraSource, Inc. 6309 Morning Dew Ct, Clarksville, MD 21029 (410)-531 -3336 or (301) 875--6454 November 20, 2018 Dr. Paulette Gaynor Office of Food Additive Safety (HFS-200) Center for Food Safety and Applied Nutrition offlCEOf ~ ~V'c SAfc,' Food and Drug Administration fOOO A0011• 5001 Campus Drive College Park, MD 20740 Subject: GRAS Notification - D-allulose (D-psicose) Dear Dr. Gaynor, On behalf of Samyang Corp., we are submitting a GRAS notification for D-allulose as a food ingredient. The enclosed document ~rovides notice of a claim that the food ingredient, D-allulose described in the enplosed notification is exempt from the premarket approval requirement of the Federal Food, Drug, and Cosmetic Act because it has been determined to be generally recognized as safe (GRAS), based on scientific procedures, for addition to foods. We bel eve that this determination and notification are in compliance with Pursuant to 21 C.F.R. Part 170, subpart E. We enclose an original copy of this notification and a CD Rom containing electronic files for your review. Please feel free to contact me if additional information or clarification is needed as you proceed with the review. We would appreciate your kind attention to this matter. Sincerely, Susan Cho, Ph.D. [email protected] Agent for Samyang Corp. 1 D-Allulose (D-Psicose) GENERALLY RECOGNIZED AS SAFE (GRAS) NOTICE FOR D-ALLULOSE (D-PSICOSE) AS A FOOD INGREDIENT On behalf of Samyang Corp. Prepared by: NutraSource, Inc.
    [Show full text]
  • Sugar Matrix
    Based on perfact’s database holding ingredients for over 250,000 products, we found that almost 300 names for sugar that appear on food labels aren’t covered by the “56 names of sugar” and SugarScience’s 61 names of sugar. The exact number depends on how one counts. This document aims to be a basis to help draw the lines between what should be considered “sugar” within the scope of those lists – and what shouldn’t. Diagram elements ANNOTATED ALTERNATIVE NAME Molecular Source Product sugar or sugar alcohol Diagram element constituting a dietary / functional fiber Molecular Source Product sugar or sugar alcohol Diagram elements explicitly ANNOTATED on 56/61 lists ALTERNATIVE NAME Molecular Source Product sugar or sugar alcohol Diagram elements explicitly or implicitly on 56/61 lists (e.g. because listed by one of its alternative name) Molecular Source Product sugar or sugar alcohol Production pathways Most common Less common This is a working document in progress. Current as of February 2019 Polysaccharides Disaccharides Monosaccharides Sugar alcohols Heat under pressure with hydrogen and Raney-nickel Feed with glucose Ribose Ribitol Ribose syrup Ribitol syrup Bacillus spp. Treat with acid E 967 E 460 Xylose Xylitol E 460I, MCC, CELLULOSE GEL, Treat with acid, pulp, and bleach Xylose syrup Xylitol syrup MICROCELLULOSE Heat under pressure with hydrogen and Raney-nickel Woody plant Cellulose Microcrystalline parts cellulose Wood Treat with acid or enzymes Treat with acid, pulp, and bleach Feed with glucose/sucrose Curdlan Agrobacterium Feed
    [Show full text]
  • Supplementary Tables Vfinal.Xlsx
    Table S3. Carbon Sources Used in the Nanostring Analysis. Concentration used in Nutrient Median Biofilm Value Figure 3 Key Dextrin 0.065 0.2% soluble fraction Low Melibionic Acid 0.072 Medium Mannan 0.081 High L-Homoserine 0.105 Very High Glycogen 0.120 2 mM Adenosine 0.127 2 mM Methyl Pyruvate 0.131 Mucic Acid 0.132 N-Acetyl-D-Glucosamine 0.138 2 mM Glycil-L-Proline 0.147 L-Alanyl-Glycine 0.149 Inosine 0.153 D-Alanine 0.156 2 mM Oxalic Acid 0.163 3-Methyl-Glucose 0.163 D-Aspartic Acid 0.165 D-Trehalose 0.169 2 mM Glycolic Acid 0.171 2 mM 2-Hydroxy Benzoic Acid 0.174 D-Glucosamine 0.177 2-Deoxy-D-Ribose 0.177 2-Deoxy Adenosine 0.178 Bromo Succinic Acid 0.179 Uridine 0.180 2 mM Pectin 0.180 Sorbic Acid 0.180 Negative Control 0.184 1,2-Propanediol 0.185 a-D-Lactose 0.186 Gelatin 0.186 D,L-a-Glycerol-Phosphate 0.186 Maltotriose 0.186 Glycerol 0.188 Inulin 0.189 Glucuronamide 0.189 N-Acetyl-D-Glucosaminatol 0.189 Lactulose 0.189 M-Inositol 0.190 3-0-b-D-Galactopyranosyl-D-Arabinose 0.191 a-Hydroxy Glutaric Acid-g-Lactone 0.193 a-Methyl-D-Galactoside 0.196 D-Psicose 0.196 L-Fucose 0.196 Succinamic Acid 0.197 D-Sorbitol 0.197 2 mM Dulcitol 0.198 D-Fructose-6-Phosphate 0.198 Sedoheptulosa 0.199 Glyoxylic Acid 0.200 Maltose 0.201 2 mM D-Ribono-1,4-Lactone 0.201 Sucrose 0.201 2 mM D-Melibiose 0.202 Mono Methyl Succinate 0.203 N-Acetyl-b-D-Mannosamine 0.204 p-Hydroxy Phenyl Acetic Acid 0.204 L-Rhamnose 0.205 2 mM D-Cellobiose 0.206 D-Glucuronic Acid 0.207 Adonitol 0.207 b-Methyl-D-Glucoside 0.207 Laminarin 0.208 Acetoacetic Acid 0.208 a-Keto-Glutaric
    [Show full text]
  • Effects of the Rare Sugars D-Psicose and D-Tagatose on the Sugar Content and Incidence of Blossom End Rot in Tomato Grown Hydroponically with Salinity Treatment
    Original Paper Environ. Control Biol., 52 (3), 155160, 2014 DOI: 10.2525/ecb.52.155 Effects of the Rare Sugars D-psicose and D-tagatose on the Sugar Content and Incidence of Blossom End Rot in Tomato Grown Hydroponically with Salinity Treatment 1 1 1 1 2 2 Yoshihiro YAMADA ,KazumasaKAKIBUCHI , Ayako KOZUKI , Yutaka ISHIDA ,KenIZUMORI , Shigeyuki TAJIMA , 2 3 3 Kazuya AKIMITSU , Takeo OHKOUCHI and Fumito KASAI 1 Shikoku Research Institute Inc., 21098 Yashima-nishimachi, Takamatsu, Kagawa 7610192, Japan 2 Faculty of Agriculture, Kagawa University, 2393 Ikenobe, Miki, Kida, Kagawa 7610795, Japan 3 Mitsui Chemicals Agro Inc., 1358 Ichimiyake, Yasu, Shiga 5202362, Japan (Received March 4, 2014; Accepted June 12, 2014) Low sugar content of fruits in winter, and blossom end rot in summer, are serious problems in the production of tomato with high soluble solids content. In the present study, we investigated the effects of the rare sugars D-psicose and D-tagatose on the sugar content of fruits and incidence of blossom end rot during several cropping seasons. We determined a highly positive correlation between the sugar content and the cumulative solar radiation during the maturation period. Treatment with D-psicose resulted in an increase in the sugar content over every cropping season. It resulted in a reduction in the in- cidence of blossom end rot, a reduction in stomatal conductance, and an increase in the relative water content in summer. On the other hand, it resulted in an increase in the incidence of blossom end rot in winter and rainy season. Treatment with D-tagatose had no effect on the sugar content, incidence of blossom end rot, water potential, stomatal conductance, or rela- tive water content.
    [Show full text]